Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.

Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, Costagliola D; FHDH ANRS CO4.

PLoS One. 2015 Dec 29;10(12):e0144746. doi: 10.1371/journal.pone.0144746. eCollection 2015.

2.

Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.

Swindells S, Jiang H, Mukherjee AL, Winters M, Bosch RJ, Katzenstein D, Aids Clinical Trials Group.

HIV Clin Trials. 2011 Mar-Apr;12(2):79-88. doi: 10.1310/hct1202-79.

3.

Role of tipranavir in treatment of patients with multidrug-resistant HIV.

Courter JD, Teevan CJ, Li MH, Girotto JE, Salazar JC.

Ther Clin Risk Manag. 2010 Oct 5;6:431-41. doi: 10.2147/TCRM.S4207.

4.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.

5.

Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.

Chin BS, Choi JY, Choi JY, Kim GJ, Kee MK, Kim JM, Kim SS.

J Korean Med Sci. 2009 Dec;24(6):1031-7. doi: 10.3346/jkms.2009.24.6.1031. Epub 2009 Nov 7.

6.

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9.

7.

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Shafer RW, Schapiro JM.

AIDS Rev. 2008 Apr-Jun;10(2):67-84. Review.

8.

Predictors of disease progression in HIV infection: a review.

Langford SE, Ananworanich J, Cooper DA.

AIDS Res Ther. 2007 May 14;4:11.

9.

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA.

PLoS Med. 2007 Jan;4(1):e36.

10.

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ.

PLoS Med. 2004 Dec;1(3):e64. Epub 2004 Dec 28.

Supplemental Content

Support Center